Dudediligence.

TransCode Therapeutics, Inc

RNAZNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$2.3MSep ’24−$5.9MDec ’24−$12.1MMar ’25−$4.3MJun ’25−$4.9MSep ’25−$13.4MDec ’25−$17.8MMar ’26−$6.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating income−$6.2M−$18.6M−$19.4M−$15.7M−$28.0M
Net income−$6.8M−$17.6M−$18.5M−$16.8M−$34.7M
Operating cash flow−$5.3M−$15.8M−$18.1M−$13.3M−$19.5M
Free cash flow−$5.5M−$15.9M−$18.1M−$13.4M−$19.5M
Cash$20.8M$5.0M$2.8M$5.8M$17.8M
Shares outstanding12.9M16.2K19.0K36.8K917.0K